University of Rome Tor Vergata
Also known as: Azienda Ospedaliera Universitaria Policlinico Tor Vergata | Azienda Ospedallera Universitaria - Policlinico Tor Vergata, Roma | Department of Systems Medicine | Director, Child Neurology and Psychiatry Unit, Systems Medicine Department, Tor Vergata University of Rome, Italy | EORTC - AZIENDA OSPEDALLERA UNIVERSITARIA - POLICLINICO TOR VERGATA, IT | Giuseppe Annino | Hematology Department, Tor Vergata University Viale Oxford, 81 00133 Rome, Italy | Internal Medicine Department, Tor Vergata University, Rome | Medical Oncology Unit, Department of Oncohematology, Policlinico Tor Vergata | Policlinico Tor Vergata | Policlinico Universitario Tor Vergata | Stefano Rizza | Tor Vergata University | Tor Vergata' University Hospital | TOR VERGATA UNIVERSITY OF ROME | Tor Vergata University, Rome, Italy | Universita di Roma Tor Vergata | University of Rome Tor Vergata | University of Tor Vergata | U.O.C. Gastroenterologia ed Endoscopia Digestiva - Azienda Ospedaliera Universitaria PTV - Policlinico
Highest phase reached
Phase 4
First clinical trial
Jan 1, 1994Last known activity
Sep 2, 2024
Timeline
1980s
- Jan 1, 1982
University of Rome Tor Vergata— Founded
Drugs by trial phase (42 distinct, 32 trials)
Phase 4 (3 own, 0 via acquisition)
Phase 3 (19 own, 0 via acquisition)
Phase 2 (5 own, 0 via acquisition)
Phase 1 (5 own, 0 via acquisition)
Other trials (10 own, 0 via acquisition)
Indications
Studied for
- Alzheimer Disease
- Ataxia
- Atherosclerosis
- Cerebellar Ataxia
- Colitis, Ulcerative
- Coronary Artery Disease
- Coronary Restenosis
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Dyslipidemias
- Friedreich Ataxia
- Hodgkin Disease
- Irritable Bowel Syndrome
- Leukemia
- Leukemia, Lymphoid
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Leukemia, Promyelocytic, Acute
- Melanoma
- Metabolic Syndrome
- Myelodysplastic Syndromes
- Myocardial Ischemia
- Neoplasms
- Parkinson Disease
- Poisoning
- Proctitis
- Proctocolitis
- Syndrome
- Ulcer
- Urinary Bladder Neoplasms
Recent trials (50)
- NCT06514573CollaboratorN/ASep 2, 2024
- NCT04937452Study chairPhase 2Jun 3, 2021
- NCT04979468Overall official - principal investigatorPhase 3Mar 23, 2021
- NCT04475120Lead sponsorPhase 2/Phase 3Apr 15, 2020
- NCT04475120Reponsible party - principal investigatorPhase 2/Phase 3Apr 15, 2020
- NCT04273165CollaboratorPhase 2Mar 20, 2020
- NCT04293783Reponsible party - principal investigatorN/AFeb 1, 2020
- NCT04293783Lead sponsorN/AFeb 1, 2020
- NCT04293783Overall official - principal investigatorN/AFeb 1, 2020
- NCT04190160Study chairN/ANov 19, 2018
- NCT04190160Lead sponsorN/ANov 19, 2018
- NCT04190160Sponsor investigatorN/ANov 19, 2018
- NCT03521232Overall official - principal investigatorPhase 1/Phase 2May 15, 2018
- NCT03250741Study directorPhase 2Jun 30, 2016
- NCT02624830CollaboratorPhase 4Nov 1, 2015
Details
- Founded
- Rome, IT Jan 1, 1982
- Last known activity
- Sep 2, 2024